

From Image to Insight

Medical imaging solutions for clinical trials

Comprehensive end-to-end imaging services from Phase I to Phase IV

- Full Service iCRO
- Collect & Hold/Read Ready
- Reader Management Services
- Consulting Services
- Rescue Studies
- Retrospective Studies
- AI Multireader Multicase (MRMC) studies

Global reach spanning 70+ countries

- Collaboration with study sites around the world
- Proven Track Record with 1400+ Research Sites and 700+ Trials
- Part of Medica group, one of the world's largest teleradiology companies

Unsurpassed Medical, Scientific and Operational Expertise

- Senior Radiologists oversight on every clinical trial
- Average of 13 years imaging experience on Operations Teams
- Rapid study initiation through streamlined, parallel processes
- Average image QC turnaround time of 1.5 days

Best in Class Reader Group of Radiologists and Imaging Experts

- Access to 300+ Readers globally
- Board certified
- Multiple therapeutic area experience and expertise
- Extensively trained through proprietary Blinded Reader and Investigator Training (BRITI)

Unmatched Oncology Expertise

- lung
- breast
- prostate
- colorectal
- head and neck
- melanoma
- pancreatic
- liver
- renal
- bladder
- gynecologic cancers
- sarcomas and gastroesophageal tumors
- lymphoma
- multiple myeloma
- neuroendocrine tumors
- glioblastoma
- bone metastases

Utilizing various evaluation criteria: RECIST 1.1, mRECIST, Lugano, RANO, PCWG3 or specially modified criteria guided by RadMD Expertise.

RECIST Plus

Additional image-based assessments that augments traditional RECIST 1.1, includes:

- Comprehensive volumetric tumor quantification
- Density analysis across lesion profiles
- Detailed morphological characterization of response and progression
- >30 qualitative non- criteria assessments, including ILD
- 60+ advanced radiomics features